Company intelligence / Profile preview
SpringWorks Therapeutics
Stamford, Connecticut, United Statesspringworkstx.com ↗
- Ownership
- Public · SWTX
- Employees
- ~305
- Development stage
- Commercial
01
Overview
SpringWorks has two FDA-approved drugs: OGSIVEO (nirogacestat) for adult desmoid tumors and GOMEKLI (mirdametinib) for neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN) in adults and children. The company continues to develop additional indications for these drugs and advance other pipeline candidates[4][5][9].
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
04
Financials
- Market cap
- $3.5B
- Total revenue
- $49.1M
- Enterprise value
- $3.3B
Beyond the preview
Go deeper on SpringWorks Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SpringWorks Therapeutics.